Plasma Galectin-3 and urine proteomics predict FEV(1) improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study()

BACKGROUND: Patients with severe allergic asthma (SAA) when treated with omalizumab may exhibit different extent of response. Identifying biomarkers that can predict the extent of treatment effectiveness in patients can be useful in personalizing omalizumab treatment. METHODS: Patients from the long...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:World Allergy Organ J
Autori principali: Riccio, Anna Maria, Mauri, Pierluigi, De Ferrari, Laura, Rossi, Rossana, Di Silvestre, Dario, Bartezaghi, Marta, Saccheri, Fabiana, Canonica, Giorgio Walter
Natura: Artigo
Lingua:Inglês
Pubblicazione: World Allergy Organization 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6992845/
https://ncbi.nlm.nih.gov/pubmed/32015785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.waojou.2019.100095
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi